UroGen Pharma Ltd.
DE ˙ DB ˙ IL0011407140
23,18 € ↑0,82 (3,67%)
2026-06-05
CENA AKCJI
SecurityDE:UR8 / UroGen Pharma Ltd.
InstitutionBlackRock, Inc.
Latest Disclosed Ownership2,519,771 shares
Ownership 5.20%
BlackRock, Inc. ownership in UR8 / UroGen Pharma Ltd.

2026-04-27 - BlackRock, Inc. has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 2,519,771 shares of UroGen Pharma Ltd. (DE:UR8). This represents 5.2 percent ownership of the company. In their previous filing dated 2025-07-16 , BlackRock, Inc. had reported owning 2,284,206 shares, indicating an increase of 10.31 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-04-27 2026-04-27 13G 2,284,206 2,519,771 10.31 5.20 4.00
2025-07-16 2025-07-16 13G/A 2,497,943 2,284,206 -8.56 5.00 -15.25
2024-11-08 2024-11-08 13G 2,497,943 2,497,943 0.00 5.90 0.00
2024-10-24 2024-10-24 13G 2,497,943 5.90
2024-05-08 2024-05-08 13G/A 1,719,304 1,669,543 -2.89 4.60 -17.86
2024-02-02 2024-02-02 13G 340,412 1,719,304 405.07 5.60 273.33
2022-07-08 2022-07-08 13G 1,728,094 340,412 -80.30 1.50 -80.52
2022-02-03 2022-02-03 13G/A 1,529,491 1,728,094 12.98 7.70 11.59
2021-02-01 2021-02-01 13G/A 1,372,863 1,529,491 11.41 6.90 6.15
2020-02-07 2020-02-07 13G 1,372,863 6.50

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F UROGEN PHARMA COM M96088105 2,845,567 244,558 9.40 51,163 -16.01 0.0001
2026-02-12 2025-12-31 13F UROGEN PHARMA COM M96088105 2,601,009 19,723 0.76 60,916 18.29 0.0010
2025-11-12 2025-09-30 13F UROGEN PHARMA COM M96088105 2,581,286 176,045 7.32 51,497 56.28 0.0009
2025-08-12 2025-06-30 13F UROGEN PHARMA COM M96088105 2,405,241 -18,222 -0.75 32,952 22.94 0.0006
2025-05-02 2025-03-31 13F UROGEN PHARMA COM M96088105 2,423,463 -43,748 -1.77 26,804 2.01 0.0006
2025-02-07 2024-12-31 13F UROGEN PHARMA COM M96088105 2,467,211 -30,732 -1.23 26,276 -17.17 0.0005
2024-11-13 2024-09-30 13F UROGEN PHARMA COM M96088105 2,497,943 303,993 13.86 31,724 -13.83 0.0007
2024-08-13 2024-06-30 13F UROGEN PHARMA COM M96088105 2,193,950 477,137 27.79 36,814 42.96 0.0008
2024-05-10 2024-03-31 13F UROGEN PHARMA COM M96088105 1,716,813 -2,491 -0.14 25,752 -0.14 0.0006
2024-02-13 2023-12-31 13F UROGEN PHARMA COM M96088105 1,719,304 521,657 43.56 25,790 53.70 0.0007
2023-11-13 2023-09-30 13F UROGEN PHARMA COM M96088105 1,197,647 99,731 9.08 16,779 47.66 0.0005
2023-08-11 2023-06-30 13F UROGEN PHARMA COM M96088105 1,097,916 813,377 285.86 11,363 332.22 0.0003
2023-05-12 2023-03-31 13F UROGEN PHARMA COM M96088105 284,539 -64,731 -18.53 2,629 -15.14 0.0001
2023-02-13 2022-12-31 13F UROGEN PHARMA COM M96088105 349,270 4,492 1.30 3,098 8.02 0.0001
2022-11-14 2022-09-30 13F UROGEN PHARMA COM M96088105 344,778 4,366 1.28 2,868 2.87 0.0001
2022-08-12 2022-06-30 13F UROGEN PHARMA COM M96088105 340,412 -1,360,364 -79.98 2,788 -81.18 0.0001
2022-05-12 2022-03-31 13F UROGEN PHARMA COM M96088105 1,700,776 -27,318 -1.58 14,816 -9.85 0.0004
2022-02-10 2021-12-31 13F UROGEN PHARMA COM M96088105 1,728,094 15,871 0.93 16,434 -42.94 0.0004
2021-11-09 2021-09-30 13F UROGEN PHARMA COM M96088105 1,712,223 -14,816 -0.86 28,800 9.21 0.0008
2021-08-11 2021-06-30 13F UROGEN PHARMA COM M96088105 1,727,039 56,434 3.38 26,372 -18.97 0.0007
2021-05-07 2021-03-31 13F UROGEN PHARMA COM M96088105 1,670,605 141,114 9.23 32,544 18.08 0.0010
2021-02-05 2020-12-31 13F UROGEN PHARMA COM M96088105 1,529,491 43,890 2.95 27,561 -3.82 0.0009
2020-11-06 2020-09-30 13F UROGEN PHARMA COM M96088105 1,485,601 19,796 1.35 28,657 -25.15 0.0011
2020-08-14 2020-06-30 13F UROGEN PHARMA COM M96088105 1,465,805 68,829 4.93 38,288 53.63 0.0015
2020-05-01 2020-03-31 13F UROGEN PHARMA COM M96088105 1,396,976 24,113 1.76 24,922 -45.60 0.0012
2020-02-13 2019-12-31 13F UROGEN PHARMA COM M96088105 1,372,863 -22,067 -1.58 45,811 37.81 0.0018
2019-11-08 2019-09-30 13F UROGEN PHARMA COM M96088105 1,394,930 56,377 4.21 33,242 -30.90 0.0014
2019-08-22 2019-06-30 13F/A-1 UROGEN PHARMA COM M96088105 1,338,553 915,970 216.76 48,107 208.18 0.0021
2019-08-13 2019-06-30 13F UROGEN PHARMA COM M96088105 1,338,553 915,970 48,107
2019-05-09 2019-03-31 13F UROGEN PHARMA COM M96088105 422,583 122,554 40.85 15,610 20.83 0.0007
2019-02-08 2018-12-31 13F UROGEN PHARMA COM M96088105 300,029 197,410 192.37 12,919 166.54 0.0007
2018-11-09 2018-09-30 13F UROGEN PHARMA COM M96088105 102,619 12,829 14.29 4,847 8.48 0.0002
2018-08-09 2018-06-30 13F UROGEN PHARMA COM M96088105 89,790 89,790 4,468 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.